Moderna Inc. [NASDAQ: MRNA] gained 3.05% on the last trading session, reaching $174.74 price per share at the time. The company report on February 18, 2021 that Moderna to Present at Upcoming Investor Conferences in February and March 2021.
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced its participation in the following upcoming virtual investor conferences:.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 1:00 p.m. ET.
Moderna Inc. represents 394.68 million in outstanding shares, while the company has a total market value of $67.10 billion with the latest information. MRNA stock price has been found in the range of $170.53 to $179.30.
If compared to the average trading volume of 23.28M shares, MRNA reached a trading volume of 6413592 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Moderna Inc. [MRNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $155.38 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Moderna Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on February 01, 2021. The new note on the price target was released on December 16, 2020, representing the official price target for Moderna Inc. stock. Previously, the target price had yet another raise from $90 to $150, while Jefferies kept a Hold rating on MRNA stock.
The Average True Range (ATR) for Moderna Inc. is set at 10.16, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 271.99. The Price to Book ratio for the last quarter was 25.00, with the Price to Cash per share for the same quarter was set at 8.53. Price to Free Cash Flow for MRNA in the course of the last twelve months was 109.48 with Quick ratio for the last quarter at 2.40.
Trading performance analysis for MRNA stock
Moderna Inc. [MRNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.74. With this latest performance, MRNA shares gained by 39.64% in over the last four-week period, additionally plugging by 156.97% over the last 6 months – not to mention a rise of 842.50% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 60.03, with the RSI for the last a single of trading hit 57.07, and the three-weeks RSI is set at 60.72 for Moderna Inc. [MRNA]. The present Moving Average for the last 50 days of trading for this stock 145.14, while it was recorded at 176.67 for the last single week of trading, and 91.57 for the last 200 days.
Moderna Inc. [MRNA]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc. [MRNA] shares currently have an operating margin of -906.38. Moderna Inc.’s Net Margin is presently recorded at -853.73.
Return on Total Capital for MRNA is now -37.83, given the latest momentum, and Return on Invested Capital for the company is -35.81. Return on Equity for this stock declined to -38.00, with Return on Assets sitting at -28.95. When it comes to the capital structure of this company, Moderna Inc. [MRNA] has a Total Debt to Total Equity ratio set at 11.57. Additionally, MRNA Total Debt to Total Capital is recorded at 10.37, with Total Debt to Total Assets ending up at 8.55. Long-Term Debt to Equity for the company is recorded at 11.27, with the Long-Term Debt to Total Capital now at 10.10.
Reflecting on the efficiency of the workforce at the company, Moderna Inc. [MRNA] managed to generate an average of -$619,302 per employee. Receivables Turnover for the company is 2.57 with a Total Asset Turnover recorded at a value of 0.03.Moderna Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.40 and a Current Ratio set at 2.40.
Moderna Inc. [MRNA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Moderna Inc. posted -0.37/share EPS, while the average EPS was predicted by analysts to be reported at -0.42/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 11.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Moderna Inc. go to 16.80%.
An analysis of insider ownership at Moderna Inc. [MRNA]
There are presently around $35,059 million, or 49.20% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: FLAGSHIP PIONEERING INC. with ownership of 30,871,524, which is approximately 0% of the company’s market cap and around 2.00% of the total institutional ownership; BAILLIE GIFFORD & CO, holding 24,312,271 shares of the stock with an approximate value of $4.25 billion in MRNA stocks shares; and VANGUARD GROUP INC, currently with $4.08 billion in MRNA stock with ownership of nearly -16.155% of the company’s market capitalization.
Positions in Moderna Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 441 institutional holders increased their position in Moderna Inc. [NASDAQ:MRNA] by around 40,085,155 shares. Additionally, 229 investors decreased positions by around 41,981,709 shares, while 68 investors held positions by with 118,566,155 shares. The mentioned changes placed institutional holdings at 200,633,019 shares, according to the latest SEC report filing. MRNA stock had 218 new institutional investments in for a total of 6,600,564 shares, while 45 institutional investors sold positions of 645,994 shares during the same period.